

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	Sirtuin 1 (SIRT1)	<i>In vitro</i> and mouse studies suggest inhibiting SIRT1 could eliminate cancer stem cells to help treat CML. In CML progenitor cells, anti-SIRT1 small interfering RNA or a small molecule inhibitor of SIRT1 decreased cell growth and induced apoptosis compared with control siRNA and vehicle control, respectively. In immunodeficient mice transplanted with CML cells, the small molecule blocked cancer cell growth compared with vehicle control. Next steps include identifying a potent SIRT1 inhibitor. EX-527, a SIRT1 inhibitor from Elixir Pharmaceuticals Inc. and Siena Biotech S.p.A., is in Phase I testing to treat Huntington's disease (HD).	Patent application filed; available for licensing	Li, L. <i>et al. Cancer Cell</i> ; published online Feb. 14, 2012; doi:10.1016/j.ccr.2011.12.020 Contact: Ravi Bhatia, City of Hope, Duarte, Calif. e-mail: rbhatia@coh.org Contact: WenYong Chen, same affiliation as above e-mail: wechen@coh.org
		SciBX 5(10); doi:10.1038/scibx.2012.252 Published online March 8, 2012		